Hemorheological tool

 

(57) Abstract:

The invention relates to medicine. It is proposed to apply ecdysterone to prevent the increase of blood viscosity and spontaneous aggregation of erythrocytes. The invention expands the Arsenal of tools that affect the rheological properties of blood. table 1.

The invention relates to medicine, specifically to pharmacology, and relates to agents affecting blood rheology.

Known means of influencing the rheological parameters of blood (blood viscosity, plasma viscosity, erythrocyte aggregation) - acetylsalicylic acid, dipyridamole, low molecular weight dextrans and other (1, 2).

The closest (prototype) is pentoxifylline (1, 3, 4). Currently, the development of hemorheological tools to reduce high blood viscosity and increased erythrocyte aggregation, very urgent due to the fact that in the pathogenesis of a large number of diseases violation of rheological properties of blood plays an important role (1).

The aim of the invention is to expand the Arsenal of hemorheological funds.

This goal is achieved using as hemorheological means of ecdysone.

Ecdysterone has a tonic, anabioticheskom, anti-inflammatory action, influence on phospholipid spectrum (6).

The use of ecdysone as hemorheological means are not described in literature. Application for a new appointment was made possible through the discovery of new properties.

New in the present invention is that ecdysterone first proposed for use as hemorheological funds. This property is not explicitly derived for the expert from the prior art. Ecdysterone can be used in patients with cardiovascular and other diseases to reduce increased blood viscosity and spontaneous aggregation of erythrocytes.

Thus, this solution meets the criteria of the invention: "novelty", "inventive step", "industrially applicable".

To establish the hemorheological properties of the extract performed 3 series of experiments. A blood examination was taken under ether anesthesia in rats of Wistar line from the common carotid artery. As the stabilizer used heparin in a final concentration of 20 IU per ml of blood to assess the aggregation of erythrocytes and 3.6% is ovale using hyperthermia. Measured initial viscosity of the blood and the amount of reversible aggregation of erythrocytes. Then blood samples in a volume of 0.5 ml was placed in a thermostat, and incubated for one hour at 42,5oC. the compounds or solvent (0.9% sodium chloride) was added 15 minutes to a temperature in a volume of 10 Ál. After heat treatment was measured by the viscosity of the blood and the rate of spontaneous aggregation of erythrocytes.

The results are shown in examples 1 - 3.

Example 1. Blood samples in a volume of 0.5 ml was placed in a water thermostat UTU-4 and incubated for one hour at 42,5oC. the viscosity of the blood was determined on capillary removeconsumer VC-4. Reversible aggregation of erythrocytes was evaluated electrometrically method on a modified microcalorimetry MKMF-1 with a graphical check on the plotter N.

Thermal effect on the blood within one hour when 42,5oC led to a pronounced viscosity increase on average by 20.5% compared with the initial value and the decrease in average 21.2% time RBC aggregation (table).

Example 2. Blood samples in a volume of 0.5 ml was placed in a water thermostat UTU-4 and incubated for one hour at 42,5oC. the viscosity of the blood Ekim method on a modified microcalorimetry MKMF-1 with a graphical check on the plotter N.

Pentoxifylline at a concentration of 10-5g/ml, included in the sample for 15 min before the temperature was lowered blood viscosity by 7.3% and caused an increase of the half-period aggregation of erythrocytes by 17.9% compared with control values (table).

The selected dose corresponds to a daily dose of the drug for intravenous administration (3).

Example 3. Blood samples in a volume of 0.5 ml was placed in a water thermostat UTU-4 and incubated for one hour at 42,5oC. the viscosity of the blood was determined on capillary removeconsumer VC-4. Reversible aggregation of erythrocytes was evaluated electrometrically method on a modified microcalorimetry MKMF-1 with a graphical check on the plotter N.

Ecdysterone at a concentration of 10-7g/ml, included in the sample for 15 min before incubation, reduced blood viscosity by 9.4% compared to control values. The half-life of RBC aggregation was by 20.7% more than in the controls (table).

Thus, ecdysterone shows a pronounced hemorheological effect, limiting the increase in blood viscosity and spontaneous aggregation of erythrocytes.

References taken into account:

1. Gabrielian, E. S., Akopov, S. E. blood Cells and

3. Mashkovsky M. D. Medicines.-M-1986.-So 1.-S. 461-462.

4. Ott E. , Lechner h, Fazekas F. Hemorheological effects of pentoxifylline on disturbed flow behavior of blood in with cerebrovascular insufficiency.//Eur.Neurol.-1983.-Suppl.1.-P. 105-107.

5. Ahram A. A., Kovganko N. In. Ecdysteroids: Chemistry and biological activity.-Minsk.-1989.

6. Cheese Century. N.//The experimental. and clinically. pharmacology.-1994.-N 5.-S. 61-66.

The use of ecdysone as a means of limiting an increase in blood viscosity and spontaneous aggregation of erythrocytes under thermal influence on blood samples.

 

Same patents:

The invention relates to medicine, namely to trombozitopatiam the chimeric immunoglobulins and their application

The invention relates to compounds of formula I:

< / BR>
where X denotes O, S, NH or NA;

Y represents substituted with R2aziridinyl, azetidinone, pyrolidine, piperidinyl, hexahydroazepin or pieperazinove the rest;

R1indicatesor< / BR>
R2represents CrH2r-COOR3;

R3denotes H, A or Ar;

A denotes alkyl with 1-6 C-atoms;

B denotes H, a, cycloalkyl with 3-7 C atoms, Ar-CkH2kor aydinbey the rest;

Ar denotes unsubstituted or mono - or twice substituted with A, Cl, Br, I, NO2, CN, OA, OH, NH2, NHA and/or NA2phenyl or benzyl residue;

"k" denotes 1, 2, 3 or 4;

"m" and "r" each, independently of one another, denote 0, 1, 2, 3 or 4; and

"n" represents 2, 3 or 4,

and their physiologically acceptable salts

The invention relates to medicine

The invention relates to a derived aydinonat or salts thereof, useful for use as a medicine, particularly as an inhibitor of activated factor X coagulation
The invention relates to medicine, namely to Pediatrics, and for the treatment of immunopathy in iron deficiency anemia in children residing in a large industrial city with a developed chemical and petrochemical industry

The invention relates to novel acyl derivatives of guanosine formula I, inosine formula II, xanthosine formula III, deoxyinosine formula IV, deoxyguanosine formula V, inosine - 2',3'-(acyclic)dialcohol formula VI or pharmaceutically acceptable salts

The invention relates to medicine, namely to trombozitopatiam the chimeric immunoglobulins and their application
The invention relates to medicine, namely to surgery, and can be used for hemostasis surface wounds parenchymatous organs

The invention relates to compounds of formula I:

< / BR>
where X denotes O, S, NH or NA;

Y represents substituted with R2aziridinyl, azetidinone, pyrolidine, piperidinyl, hexahydroazepin or pieperazinove the rest;

R1indicatesor< / BR>
R2represents CrH2r-COOR3;

R3denotes H, A or Ar;

A denotes alkyl with 1-6 C-atoms;

B denotes H, a, cycloalkyl with 3-7 C atoms, Ar-CkH2kor aydinbey the rest;

Ar denotes unsubstituted or mono - or twice substituted with A, Cl, Br, I, NO2, CN, OA, OH, NH2, NHA and/or NA2phenyl or benzyl residue;

"k" denotes 1, 2, 3 or 4;

"m" and "r" each, independently of one another, denote 0, 1, 2, 3 or 4; and

"n" represents 2, 3 or 4,

and their physiologically acceptable salts
The invention relates to medicine and agriculture, in particular to a method of extraction of biologically active compounds from plant material
Up!